Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Type 2 Diabetes
Interventions: Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 108
States / cities: Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: TRE plus SOC, SOC, TRE; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: metformin hydrochloride 1000 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes Mellitus, Type 1
Interventions: Fast-acting insulin aspart, iLet™; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions: Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 40 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Schizophrenia
Interventions: Functional Adaptation Skills Training (FAST); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Parkinson
Interventions: Prism adaptation; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Healthy
Interventions: Menu: calories=yes, value pricing=no, Menu: calories=yes, value pricing = yes, Menu: calories=no, value pricing = no; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 16 Years and older
Enrollment: 605 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Ondansetron, Zofran®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Disorder of Vitamin B12
Interventions: Vitamin B12; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 49 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Obstructive Sleep Apnea
Interventions: Encore Tongue Suspension System; Device
Lead sponsor: Siesta Medical, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Normal Physiology
Interventions: In vivo MRS, fMRI, EEG/EOG, Stimulation tasks, NSPRD, Structural MRI; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Metabolic Diseases
Interventions: water-only 24-hour fasting once per week for 6 weeks; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 30 Years to 69 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Healthy
Interventions: Losartan potassium/Hydrochlorothiazide; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: metformin HC1 750 mg extended-release tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions: Venglustat GZ/SAR402671; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Maribavir; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Congenital Hyperinsulinism
Interventions: Exendin-(9-39), Vehicle; Drug · Other
Lead sponsor: Diva De Leon; Other
Eligibility: 7 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Gabapentin 800 mg Tablets, single dose, NEURONTIN® 800 mg Tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Peripheral Artery Disease
Interventions: Fitbit Physical Activity Monitor, mHealth Glucometer, mHealth Blood Pressure; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Osteoarthritis, Knee
Interventions: Exercise; Behavioral
Lead sponsor: Helen Hayes Hospital; Other
Eligibility: 60 Years to 89 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: West Haverstraw, New York

Conditions: Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions: OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion; Drug
Lead sponsor: Medicines for Malaria Venture; Other
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miramar, Florida

Search by objective public record fields.

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Natural History Study for DNA Repair Disorders

Rehabilitative Training for Older People With Schizophrenia

Prism Adaptation Treatment of Parkinson's Disease

Effect of Nutrition Labeling on Fast Food Choices

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption

FAST as a Treatment for Obstructive Sleep Apnea

Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

The Fasting II Study

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Effect of Venglustat in Patients With Renal Impairment

A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

A Comparative Analysis of Two Types of Exercise on Outcomes Following Total Knee Arthroplasty

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects